CTKB - Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market Bullish Analyst Says | Benzinga
Stephens initiated coverage on Cytek Biosciences Inc (NASDAQ: CTKB), a manufacturer and supplier of flow cytometry products and services.
Analysts Mason Carrico and Jacob Krahenbuhl view Cytek's full spectrum technology as differentiated and believe the performance advantages of its platforms are compelling to customers in higher-growth segments of the cell analysis market.
Stephens initiates with an Overweight rating and a price target of $9.
Cytek has continually surpassed the overall cell analysis market's growth, upholding a disciplined cost strategy and positioning itself as one of the few ...